Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance.
about
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malariaTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaAdvances in understanding the genetic basis of antimalarial drug resistanceA systematic in silico search for target similarity identifies several approved drugs with potential activity against the Plasmodium falciparum apicoplastExtreme mutation bias and high AT content in Plasmodium falciparum.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoUse of proscribed chloroquine is associated with an increased risk of pfcrt T76 mutation in some parts of Ghana.Limited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in UgandaPlasmodium drug targets outside the genetic control of the parasite.Modeling the effects of relapse in the transmission dynamics of malaria parasites.Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasitesAssessing anti-malarial drug effects ex vivo using the haemozoin detection assay.Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the futureMultiplex PCR and oligonucleotide microarray for detection of single-nucleotide polymorphisms associated with Plasmodium falciparum drug resistance.Drug-resistant malaria - an insight.Transporter-mediated uptake into cellular compartments.Preparation of bicyclic 1,2,4-trioxanes from gamma,delta-unsaturated ketonesSynthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration.Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso.Plasmodium falciparum Genetic Diversity in Continental Equatorial Guinea before and after Introduction of Artemisinin-Based Combination TherapyMalaria and iron: history and review.ABC transporters involved in drug resistance in human parasites.Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China.In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin.Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277).Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis.
P2860
Q24614989-EA32AE52-65DC-4E72-94B0-05EC28D2F9DCQ28125904-B596C17E-75E7-4208-97BB-F5558CE76D27Q28471642-D213A1FA-A122-41EB-AA4D-642B17E94099Q28488932-D77FA20B-E862-451E-AF41-D83B5F8579EAQ33558392-A1A96AAC-81D5-47ED-A38E-EACE40ED03CEQ33676088-11BF679F-485B-4E1B-A73E-541B54A4C241Q33723453-825691C1-0707-4634-B10B-116A6D76C22DQ33826359-F9E82F43-366C-4D2D-A21E-6BD16D6DD372Q33870057-F0BB0EAF-9285-4271-B727-007F458F9BA9Q34529355-8FAEB948-8EB5-4A09-97A9-520CA982A3DAQ34678568-E223CE7E-0049-4AD7-8D59-3F081CBF5DA8Q35237540-395FC360-775C-4B3C-A359-9325B4649AE0Q35270425-541FDC40-1949-4DAC-941B-66B09924ECE1Q35368698-2AD54DCE-70E6-43AF-996F-24DD9ADA092BQ36012531-FD39106B-FF56-4194-B5E9-30E6FB327214Q36747592-80642C11-08DE-43A2-B12E-979CBC481EDFQ36933785-BB918AC3-E205-4278-A14B-6EBD37D0B4F3Q36985076-88A6399E-F300-4887-937C-6DF6F01715F9Q37132632-B872234C-7DBF-4EC7-926D-8A696D19C533Q37144874-3A541A1F-4011-4691-89AD-E46C209C03ADQ37190605-6E7279BA-D4FA-484E-AACF-4AFAA3E1ED2AQ37402952-8DE0114C-FA78-4F78-9497-36E6A27A0BBDQ37527013-3117902E-2D52-41E3-9B3D-080F46722E26Q37538729-76A23628-9B3C-44D6-AC7B-4A1E77B4CCF2Q37599856-712D6A1B-00C4-4873-9D02-2087BE1D8987Q37941754-E5197B1A-7D0B-45ED-997A-C2BF4DC14626Q39208596-11150A69-5BE7-4549-A8C9-DB1C9E027A2CQ39224800-96F8F3D1-46A0-4203-AB91-743322686CEEQ41944932-D4B79DD2-3056-4DFD-97C7-96A92A50E519Q42018084-55522B90-B6DB-49CE-A494-A1B6A4AD927CQ42112110-D4C61365-550B-4905-B8F7-75722B582A5E
P2860
Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antimalarial drugs: recent adv ...... d their clinical significance.
@ast
Antimalarial drugs: recent adv ...... d their clinical significance.
@en
type
label
Antimalarial drugs: recent adv ...... d their clinical significance.
@ast
Antimalarial drugs: recent adv ...... d their clinical significance.
@en
prefLabel
Antimalarial drugs: recent adv ...... d their clinical significance.
@ast
Antimalarial drugs: recent adv ...... d their clinical significance.
@en
P1476
Antimalarial drugs: recent adv ...... d their clinical significance.
@en
P2093
Woodrow CJ
P2888
P304
P356
10.1007/S00018-006-6071-1
P577
2006-07-01T00:00:00Z